From Analysis:
Protein aggregation cross-seeding across neurodegenerative diseases
Protein aggregation cross-seeding across neurodegenerative diseases?
Specific lipid perturbations (bis(monoacylglycero)phosphate enrichment, cardiolipin externalization) create membrane microenvironments that expose distinct amyloid-competent conformers, allowing one misfolded protein to template another's beta-sheet formation with lipid-mediated specificity.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Lysosomal Membrane Stress
PLD3 Dysfunction or Mutation"]
B["BMP Bis-Monoacylglycerophosphate Enrichment
Late Endosome Lipid Signature"]
C["Cardiolipin Externalization
Mitochondrial Lipid Exposed"]
D["Membrane Microenvironment Switch
Unique Lipid Topology Created"]
E["Amyloid-Competent Conformer Exposure
Protein Misfolding Nucleation Sites"]
F["Cross-Seeding Recognition Events
Specificity Switched by Lipid Context"]
G["Multi-Protein Aggregate Propagation
Tau-SNCA-TDP43 Co-Seeding"]
A --> B
A --> C
B --> D
C --> D
D --> E
E --> F
F --> G
style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
The proposal argues that galectin-3 simultaneously recruits Aβ42, α-synuclein, and TDP-43 to damaged endolysosomal membranes, creating a high-concentration environment that favors cross-nucleation. However, the cited evidence demonstrates only co-localization, not catalysis. Galectin-3 is a lectin with established carbohy
The presented hypotheses are mechanistically interesting but pre-clinical, occupying an intermediate translational readiness level between basic discovery and therapeutic development. The galectin-3 proposal in particular represents a sophisticated speculation that requires significant experimental derisking before reaching IND-enabling studies. I will therefore evaluate translational potential not against an abstract standard, but against what is achievable
{"ranked_hypotheses":[{"rank":1,"title":"Galectin-3 as Damage-Sensor Scaffold for Multimeric Cross-Seeding at Compromised Endo/Lysosomal Membranes","mechanism":"Galectin-3's carbohydrate recognition domain binds exposed glycans on ruptured endolysosomal membranes while its intrinsically disordered N-terminus provides a phase-separated condensation surface that recruits aggregation-prone proteins (Aβ42, α-synuclein, TDP-43) into localized high-concentration environments favoring cross-nucleation.","target_gene":"LGALS3","confidence_score":0.55,"novelty_score":0.75,"feasibility_score":0.40,"im
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for PLD3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
LGALS3__galectin_3_["LGALS3 (galectin-3)"] -->|promotes| lysosomal_quality_control["lysosomal quality control"]
cellular_stress["cellular stress"] -->|causes| LGALS3_upregulation["LGALS3 upregulation"]
TDP_43_pathology["TDP-43 pathology"] -->|causes| cognitive_decline_in_Alzh["cognitive decline in Alzheimer's patients"]
lecanemab_donanemab["lecanemab/donanemab"] -->|promotes| amyloid_clearance["amyloid clearance"]
LGALS3__galectin_3__1["LGALS3 (galectin-3)"] -->|promotes| cross_nucleation_at_damag["cross-nucleation at damaged endolysosomal membranes"]
endolysosomal_membrane_da["endolysosomal membrane damage"] -->|enables| cross_seeding_of_aggregat["cross-seeding of aggregation-prone proteins"]
LGALS3__galectin_3__2["LGALS3 (galectin-3)"] -->|promotes| amyloid_plaque_pathology["amyloid plaque pathology"]
steric_zipper_hexapeptide["steric zipper hexapeptide inhibitors"] -.->|inhibits| cross_seeding_between_amy["cross-seeding between amyloidogenic proteins"]
steric_zipper_motifs["steric zipper motifs"] -->|promotes| amyloid_nucleation["amyloid nucleation"]
traumatic_brain_injury["traumatic brain injury"] -->|increases| cross_disease_protein_agg["cross-disease protein aggregation risk"]
viral_infections["viral infections"] -->|increases| cross_disease_protein_agg_3["cross-disease protein aggregation risk"]
specific_lipid_perturbati["specific lipid perturbations"] -->|modulates| cross_seeding_specificity["cross-seeding specificity"]
style LGALS3__galectin_3_ fill:#4fc3f7,stroke:#333,color:#000
style lysosomal_quality_control fill:#4fc3f7,stroke:#333,color:#000
style cellular_stress fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_upregulation fill:#4fc3f7,stroke:#333,color:#000
style TDP_43_pathology fill:#ef5350,stroke:#333,color:#000
style cognitive_decline_in_Alzh fill:#ef5350,stroke:#333,color:#000
style lecanemab_donanemab fill:#4fc3f7,stroke:#333,color:#000
style amyloid_clearance fill:#4fc3f7,stroke:#333,color:#000
style LGALS3__galectin_3__1 fill:#4fc3f7,stroke:#333,color:#000
style cross_nucleation_at_damag fill:#4fc3f7,stroke:#333,color:#000
style endolysosomal_membrane_da fill:#4fc3f7,stroke:#333,color:#000
style cross_seeding_of_aggregat fill:#4fc3f7,stroke:#333,color:#000
style LGALS3__galectin_3__2 fill:#4fc3f7,stroke:#333,color:#000
style amyloid_plaque_pathology fill:#ef5350,stroke:#333,color:#000
style steric_zipper_hexapeptide fill:#4fc3f7,stroke:#333,color:#000
style cross_seeding_between_amy fill:#4fc3f7,stroke:#333,color:#000
style steric_zipper_motifs fill:#4fc3f7,stroke:#333,color:#000
style amyloid_nucleation fill:#4fc3f7,stroke:#333,color:#000
style traumatic_brain_injury fill:#ef5350,stroke:#333,color:#000
style cross_disease_protein_agg fill:#ef5350,stroke:#333,color:#000
style viral_infections fill:#ef5350,stroke:#333,color:#000
style cross_disease_protein_agg_3 fill:#ef5350,stroke:#333,color:#000
style specific_lipid_perturbati fill:#4fc3f7,stroke:#333,color:#000
style cross_seeding_specificity fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-01 | completed
No comments yet. Be the first to comment!